World's First CAR-T Therapy for Solid Tumors Approved

For the first time in medical history, a cellular therapy designed to fight solid tumors has received regulatory approval, opening a new frontier in cancer treatment.

CARsgen Therapeutics has received approval from China's National Medical Products Administration for satri-cel, a CAR-T therapy targeting advanced gastric and gastroesophageal junction cancers. The treatment is designed for patients whose cancer has progressed after two previous treatment attempts.

This marks a turning point for CAR-T therapy, which has worked remarkably well for blood cancers but struggled against the complex biological barriers of solid tumors. Scientists have been working toward this breakthrough since the late 1990s, when early tests began on ovarian and other solid cancers.

Gastric cancer is the fifth most common cancer worldwide, with over one million new cases and 750,000 deaths each year. China and East Asia account for 40% of global cases, driven by risk factors including H. pylori infection and dietary exposures.

The therapy works by targeting CLDN18.2, a protein highly expressed in gastric and pancreatic cancers but rarely found in healthy tissues. Doctors extract a patient's own immune cells, engineer them to recognize and destroy cancer cells, then infuse them back into the body.

What makes satri-cel different is its approach to the tumor microenvironment. The treatment includes a special preconditioning strategy using low-dose chemotherapy to help the engineered cells penetrate tumors and work more effectively.

A randomized study published in The Lancet in 2025 showed meaningful results in heavily pretreated patients. The therapy demonstrated both effectiveness and a manageable safety profile, providing some of the strongest evidence yet that CAR-T can work against solid tumors.

The Ripple Effect

Beyond this approval, the therapy has already earned breakthrough designations from the FDA and special status from European regulators. CARsgen is now testing satri-cel in earlier stages of gastric cancer, in pancreatic cancer, and in patients outside China.

The approval has energized the entire field of solid tumor immunotherapy. Multiple companies are now developing similar approaches targeting CLDN18.2 and other proteins, racing to replicate or improve on these results.

For cancer specialists and patients, this isn't just a new treatment option but proof that engineered cellular therapies can overcome obstacles that seemed insurmountable just years ago.

The field has finally crossed a milestone that eluded oncology for decades, and thousands of patients may soon benefit from this breakthrough approach to fighting cancer.